Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure

Hypertension

Volumn 32, Issue 4, 1998, Pages 746-752

  Brodsky, Sergey ^a   Gurbanov, Konstantin ^a   Abassi, Zaid ^a   Hoffman, Aaron ^a   Ruffolo Jr , Robert R ^b   Feuerstein, Giora Z ^b   Winaver, Joseph ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Angiotensin antagonist; Angiotensin II; Fistula, aortocaval; Hemodynamics; Hypertrophy; Rats; Renal circulation

Indexed keywords

EPROSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTOCAVAL FISTULA; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFECT; HEART HYPERTROPHY; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM EXCRETION; URINARY EXCRETION;

EID: 0031724276     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.32.4.746     Document Type: Article

References (40)

1. Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int. 1987;31:1402-1415.
2. Watkins L Jr, Burton JA, Haber E, Cant JR, Smith FW, Barger AC. The renin-angiotensin-aldosterone system in congestive failure in conscious dogs. J Clin Invest. 1976;57:1606-1617.
3. Dzau VJ, Colucci WS, Hollenberg NK, Williams RE. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation. 1981;63:645-651.
4. Packer M. Adaptive and maladaptive actions of angiotensin II in patients with severe congestive heart failure. Am J Kidney Dis. 1987;10:66-73.
5. Katz AM. Angiotensin II: hemodynamic regulator or growth factor? J Mol Cell Cardiol. 1990;22:739-747.
6. Winaver J, Hoffman A, Burnett JC Jr, Haramati A. Hormonal determinants of sodium excretion in rats with experimental high-output heart failure. Am J Physiol. 1988;254:R776-R784.
7. Ichikawa I, Pfeffer JM, Pfeffer MA, Hosteller TH, Brenner BM. Role of angiotensin II in the altered renal function of congestive heart failure. Circ Res. 1984;55:669-675.
8. Ichikawa I, Yoshioka T, Fogo A, Kon V. Role of angiotensin II in altered glomerular hemodynamics in congestive heart failure. Kidney Int. 1990; 38:S-123-S-126.
9. Hall JE, Brands MW. The renin-angiotensin-aldosterone systems: renal mechanisms and circulatory homeostasis. In: Seldin DW, Giebisch G, eds. The Kidney: Physiology and Pathophysiology. New York, NY: Raven Press; 1992:1455-1504.
10. Pfeffer JM, Pfeffer MA, Braunwald E. Hemodynamic benefits and prolonged survival with long-term captopril therapy in rats with myocardial infarction and heart failure. Circulation. 1987;75(suppl I):I-149-I-155.
11. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
12. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Werthheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669-677.
13. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
14. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. J Clin Invest. 1997;99: 1926-1935.
15. Farhy RD, Carretero OA, Ho KL, Scicli AG. Role of kinins and nitric oxide in the effects of angiotensin-converting enzyme inhibitors on neointima formation. Circ Res. 1993;72:1202-1210.
16. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med. 1996;334:1649-1654.
17. Bauer JH, Reams GP. The angiotensin II type 1 receptor antagonists: a new class of antihypertensive drugs. Arch Intern Med. 1995;155:1361-1368.
18. Sweet CS, Rucinska EJ. Losartan in heart failure: preclinical experiences and initial clinical outcomes. Eur Heart J. 1994;15:139-144.
19. Awan NA, Mason DT. Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure. Am Heart J. 1996;131:177-185.
20. Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKock M. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 1993;88:1602-1609.
21. Crazier I, Ikram H, Awan NA, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, Rucinska E. Losartan in heart failure: hemodynamic effects and tolerability. Circulation. 1995;91:691-697.
22. Fitzpatrick MA, Rademaker MT, Charles CJ, Yandle TG, Espiner EA, Ikram H. Angiotensin II receptor antagonism in ovine heart failure: acute hemodynamic, hormonal, and renal effects. Am J Physiol. 1992;263:H250-H256.
23. Abassi ZA, Kelly G, Golomb E, Klein H, Reiser HR. Losartan improves the natriuretic response to ANF in rats with high-output heart failure. J Pharmacol Exp Ther. 1994;268:224-268.
24. Spinale FG, de Gasparo M, Whitebread S, Hebbar L, Clair MJ, Melton M, Krombach SR, Mukherjee R, Iannini JP, O SJ. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure, I: effects on left ventricular performance and neurohormonal systems.
25. Price DA, De'Oliveira JM, Fisher NDL, Hollenberg NK. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension. 1997;30:240-246.
26. Brooks DP, Fredrickson TA, Weinstock J, Ruffolo RR Jr, Edwards RM, Gellai M. Antihypertensive activity of the non-peptide angiotensin II receptor antagonist. SK&F 108566, in rats and dogs. Arch Pharmacol. 1992;345:673-678.
27. Hoffman A, Bumett JC Jr, Haramati A, Winaver J. Effects of atrial natriuretic factor in rats with experimental high-output heart failure. Kidney Int. 1988;33:656-661.
28. Abassi ZA, Gurbanov K, Mulroney SE, Potlog C, Opgenorth TJ, Hoffman A, Haramati A, Winaver J. Impaired nitric oxide-mediated renal vasodilation in rats with experimental heart failure: role of angiotensin II. Circulation. 1997;96:3655-3664.
29. Calderone A, Takahashi N, Izzo NJ, Thaik CM, Colucci WS. Pressure-and volume-induced left ventricular hypertrophies are associated with distinct myocyte phenotypes and differential induction of peptide growth factor mRNAs. Circulation. 1995;92:2385-2390.
30. Ruzicka M, Yuan B, Harmsen E, Leenen FHH. The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats. Circulation. 1992;87:921-930.
31. Stumpe KU, Solle H, Klein H, Knick F. Mechanism of sodium and water retention in rats with experimental heart failure. Kidney Int. 1973;4:309-317.
32. Abassi Z, Haramati A, Hoffman A, Burnett JC Jr, Winaver J. Effect of converting-enzyme inhibition on renal response to ANF in rats with experimental heart failure. Am J Physiol. 1990;259:R84-R89.
33. Gurbanov K, Rubinstein I, Hoffman A, Abassi Z, Better OS, Winaver J. Differential regulation of renal regional blood flow by endothelin-1. Am J Physiol. 1996;271:F1166-F1172.
34. Fuhr J, Kaczmarczyk J, Kruttgen CD. Eine einfache colorimetrische Methode zur Inulinbestimmung fur Nierencleartanceuntersuchungen bei Stowechselgesunden und Diabetikern. Klin Wochenschr. 1955;33:729-730.
35. Villarreal D, Freeman RH. ANF and the renin-angiotensin system in the regulation of sodium balance: longitudinal studies in experimental heart failure. J Lab Clin Med. 1991;118:515-522.
36. Maeda Y, Wada A, Tsutamoto T, Fukai D, Kinoshita M. Chronic effects of ANG II antagonist in heart failure: improvement of cGMP generation from ANP. Am J Physiol. 1997;272:H2139-H2145.
37. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med. 1993;153:937-942.
38. Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation. 1997;96:4065-4082.
39. Pieruzzi F, Abassi Z, Keiser HR. Expression of renin-angiotensin system components in the heart, kidneys and lungs of rats with experimental heart failure. Circulation. 1995;92:3105-3112.
40. Smits JFM. Angiotensin II receptor blockade after myocardial infarct in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol. 1992;20:772-778.